Brain natriuretic peptide levels in the obstructive sleep apnoea/hypopnoea syndrome Source: Eur Respir J 2005; 26: Suppl. 49, 355s Year: 2005
Renin and aldosterone levels in obstructive sleep apnea syndrome patients Source: International Congress 2015 – Inflammation, biomarkers and hypoxia in sleep disordered breathing Year: 2015
NT-pro BNP is a marker for cardiovascular dysfunction due to obstructive sleep apnea syndrome Source: Annual Congress 2010 - Nocturnal cardiology: chronic heart failure, acute chest syndrome, coronary artery disease and collagen vascular disease Year: 2010
Natriuretic peptide in sleep apnea – relation with hypoxia Source: Eur Respir J 2007; 30: Suppl. 51, 334s Year: 2007
8-isoprostanes and resistin as markers of vascular damage in non-hypersomnolent obstructive sleep apnea patients Source: International Congress 2016 – Effects of hypoxia and sleep apnoea on the lung, heart, and vessels Year: 2016
Serum midkine levels in patients with obstructive sleep apnea Source: International Congress 2015 – Inflammation, biomarkers and hypoxia in sleep disordered breathing Year: 2015
Changes in inflammatory mediators as a result of intermittent hypoxia in obstructive sleep apnea syndrome Source: International Congress 2016 – Hypoxia, oxidative stress, and biomarkers in obstructive sleep apnoea Year: 2016
Relationship between echocardiographic assessment and plasma endothelin-1 levels in obese patients with or without obstructive sleep apnea Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015
Plasma adiponectin levels and hypoxic stress in patients with obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2004 - Systemic and metabolic effects from OSA Year: 2004
Alteration of inflammatory mediators in patients with obstructive sleep apnea Source: Annual Congress 2013 –A metabolic medley: sleep disordered breathing Year: 2013
BNP or VEGF levels do not predict disease severity in obstructive sleep apnoea syndrome (OSAS) Source: Eur Respir J 2005; 26: Suppl. 49, 40s Year: 2005
Plasma orexin-A levels in patients with obstructive sleep apnea syndrome Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea: Effect of continuous positive airway pressure treatment Source: Annual Congress 2013 –A metabolic medley: sleep disordered breathing Year: 2013
Association between metabolic disturbances and inflammatory markers in obstructive sleep apnea (OSAS) patients Source: Annual Congress 2008 - Metabolic syndrome and systemic inflammation in obstructive sleep apnoea Year: 2008
Hepcidin: the new marker for determining nocturnal hypoxia in patients with obstructive sleep apnea Source: Annual Congress 2009 - Systemic consequences of sleep-disordered breathing Year: 2009
Evaluation of 8-isoprostane as a biomarker of oxidative stress in children with obstructive sleep apnea syndrome Source: Annual Congress 2012 - Sleep monitoring, lung function and inflammation in childhood Year: 2012
Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 332s Year: 2004
Cardiovascular diseases are responsible for increased plasma NT-proBNP level in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2012 - Physiology, obesity and the downstream effects of OSA Year: 2012
Metabolic disturbances in patients with obstructive sleep apnoea syndrome Source: Eur Respir Rev 2007; 16: 196-202 Year: 2007
Ventilatory response amongst patients with obstructive sleep apnoea Source: International Congress 2016 – Central sleep apnoea and the central regulation of obstructive and central sleep apneoa Year: 2016